Apr 13 | News
Investment in research and development by members of the Pharmaceutical Research and Manufacturers of America remained strong at $49.5 billion in 2011, as the sector adapts to meet the challenges of evolving science, a changing marketplace and a difficult economic environment.
|
Oct 4 2011 | Video
Chris Viehbacher, PhRMA's chairman and the CEO of Sanofi shares his thoughts about the value of new medicines, Medicare Part D, what inspires him each day, and what is "not only our mission, but our responsibility."
|
Aug 23 2011 | Video
Endo Pharmaceuticals' Robert Cobuzzi speaks about the challenges emerging biopharmaceutical companies face.
|
Aug 5 2011 | Video
Merck's Dr. Rupert Vessey explains the importance of new medicines in treatment of various forms of arthritis.
|
Jun 24 2011 | News
WASHINGTON (AP) — States cannot stop drug manufacturers and
data-mining companies from using information about the prescription drugs
individual doctors like to prescribe, the Supreme Court ruled Thursday.
|
Mar 22 2011 | Video
Kendra Martello, PhRMA Assistant General Counsel, explains the difference between foreign-sourced active ingredients used in FDA-approved drugs and imported drugs from foreign countries that are not FDA approved.
|
Mar 21 2011 | Video
Tom Kubic, President and CEO of the Pharmaceutical Security Institute and a Board Member of the Partnership for Safe Medicines (two organizations on the front lines of this issue) discusses the global counterfeit drug trade.
|
Feb 23 2011 | Video
Sigma-Tau Pharmaceuticals' Gregg Lapointe shares his company's unique approach and rare dedication to finding treatments and cures for patients suffering from rare diseases
|
Jan 26 2011 | Video
Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released a statement following the President's State of the Union address. The video details his views on pharmaceutical innovation.
|
Jan 17 2011 | Video
PhRMA Chairman and Sanofi Aventis CEO Chris Viehbacher describes his vision for the pharma/biopharma industry in 2011.
|